Established in Hyderabad, India in 1978, Gland Pharma has grown over the years from a contract manufacturer of small volume liquid parenteral products, to become one of the largest and fastest growing injectable-focused companies, with a global footprint across 60 countries, including the United States, Europe, Canada, Australia, India and other markets. We operate primarily under a business to business (B2B) model and have an excellent track record in the development, manufacturing and marketing of complex injectables. This presence across the value chain has helped us witness exponential growth. We are promoted by Shanghai Fosun Pharma, a global pharmaceutical major.
With our proven performance in complex injectables across development, manufacturing and marketing, we are sufficiently enabled to meet diverse injectable needs across a vast range of specific requirements. Our 22 production lines for finished formulations across four facilities are complimented by three facilities for Active Pharmaceutical Ingredients (API). Plans are underway to augment the present manufacturing capacity of approximately 750 million units in the medium term to support future growth.
The ability to provide therapeutic medicines on the best quality parameters and at the right price, is the overriding objective for us at Gland Pharma. All other factors remaining equal, backward integration and economies of scale play a significant role in providing quality medications at the right price. Over the years, we have been able to move ahead on both those counts, to establish a presence across the entire value chain in Injectables.
A manufacturing base with installed capacity of 750 million units per annum spread over seven facilities; proven Research and Development wing; pan-India and global distribution and sales network; affiliation with national and state level healthcare institutions; compliance with all necessary regulatory boards; and a high level of approvals and pending filings in our area of operations, all contribute to our standing in the pharma domain.
Our family of investors and other stakeholders are the driving force that gives us a sharp focus on good governance in all our areas of operations and services. And by doing so, we are reiterating our firm resolve to deliver value and satisfaction.
The audited financial statements of Gland Pharma Limited (“Company”), as at and for the financial years ended March 31, 2018, March 31, 2019 and March 31, 2020 and the audit reports thereon dated August 21, 2018, August 29, 2019 and June 3, 2020, respectively (collectively, the “Financial Statements”), have been uploaded here by the Company solely to comply with the requirements specified in the Securities and Exchange Board of India (Issue of Capital and Disclosure Requirement) Regulations, 2018, as amended (“SEBI ICDR Regulations”).
Please note that the Financial Statements do not constitute a draft red herring prospectus, red herring prospectus or final prospectus, a statement in lieu of a prospectus, an offering circular, an offering memorandum, an advertisement, an offer or a solicitation of any offer or an offer document to purchase or sell any securities under the Companies Act, 2013, the SEBI ICDR Regulations, or any other applicable law in India or elsewhere in the world. The Financial Statements should not be considered as part of information that any investor should consider to subscribe for or purchase any securities of the Company should not be relied upon or used as a basis for any investment decision. Anyone placing reliance on the Financial Statements, or any other information on the website of the Company would be doing so at their own risk.
The information contained herein does not constitute an offer for sale of, or solicitation of an offer to buy, the securities of the Company in the United States or in any other jurisdiction. Securities may not be offered or sold in the United States absent registration or an exemption from registration under the U.S. Securities Act of 1933, as amended.
While care has been taken in preparing the Financial Statements, none of the Company or any of its advisors, nor any book running lead managers or selling shareholders, nor any of their respective employees, directors, affiliates, agents or representatives accept any liability whatsoever for any loss howsoever arising from any information presented or contained in the Financial Statements, or the opinions expressed therein. None of the foregoing shall be liable for any direct or indirect losses arising from the use thereof and the viewers are requested to use the information contained herein at their own risk.
These Financial Statements should not be copied, reproduced, re-circulated, re-distributed, published or advertised in any media, website or otherwise, in any form or manner, in part or as a whole, without the express consent in writing from the Company. Any unauthorized use of the Financial Statements contained herein is prohibited. Accordingly, any persons in possession of the aforesaid should inform themselves about and observe any such restrictions. Information contained in the Financial Statements is provided “as is” without warranty of any kind, either expressed or implied, including any warranty of fitness for a particular purpose. No reliance should be placed on, the accuracy, fairness or completeness of the information presented or contained in these Financial Statements. Further, past performance is not necessarily indicative of future results. Any opinion expressed on the Financial Statements are subject to change without notice.
The Financial Statements are only current as of the dates specified therein and neither the Company nor any of its respective advisors or representatives is under any obligation to update you in the event the information in the Financial Statements becomes stale or inaccurate. You must make your own assessment of the relevance, accuracy and adequacy of the information contained in the Financial Statements and must make such independent investigation as you may consider necessary or appropriate for such purpose.